Pharmaceutica Analytica Acta

Formulation and optimization of orodispersible tablets of Flutamide

4^th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems

March 24-26, 2014 Hilton San Antonio Airport, San Antonio, USA

Kadria A Elkhodairy, Maha A Hassan and Samar A Afifid

Scientific Tracks Abstracts: Pharmaceut Anal Acta

Abstract:

The present study aimed to formulate orodispersible tablets of flutamide (FTM) to increase its bioavailability. Orodispersible tablets were prepared by direct compression technique using three different approaches namely; super-disintegration, effervescence and sublimation. Different combined approaches were proposed and evaluated to optimize tablet characteristics. Sodium starch glycolate (SSG) was used as the super disintegrant. The prepared powder mixtures were subjected to both pre and post compression evaluation parameters including; IR spectroscopy, micromeritics properties, tablet hardness, friability, wetting time, disintegration time and in-vitro drug release. IR studies indicated that there was no interaction between the drug and the excipients used except Ludipress. The results of micromeritics studies revealed that all formulations were of acceptable to good flow ability. Tablet hardness and friability indicated good mechanical strength. Wetting and dispersion times decreased from 46 to 38 s by increasing the SSG concentration from 3.33 to 6.66%w/w in tablets prepared by super disintegration method. The F8 formulation which was prepared by combined approaches of effervescence and super disintegrant addition gave promising results for tablet disintegration and wetting times but failed to give faster dissolution rate. The incorporation of 1:5 solid dispersion of FTM: PEG6000 instead of the pure drug in the same formulation increased the drug release rate from 73.12 to 96.99% after 15 min. This increase in the dissolution rate may be due to the amorphization of the drug during the solid dispersion preparation. The presence of the amorphous form of the drug was shown in the IR spectra.

Biography :

Kadria A Elkhodairy received her Ph.D. in Industrial Pharmacy from the University of Alexandria, Egypt. She has over 25 years of experience in the field of pharmaceutical technology during which she published 49 manuscripts in peer reviewed journals concerning microparticles, nanoparticles, colon drug targeting, and in-vivo evaluation of dosage forms. She has focused on oral formulation development and Novel drug delivery technologies. Since 2010, she is a professor of pharmaceutics at King Saud University, Saudi Arabia, and currently a reviewer in many international journals.